RxDoctor Payments Data

Janet Bradley

Psychiatry · New Orleans, LANPI 1487774527

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 27.5% of the total. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,133in general payments, 2019–2025

Across 295 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$803
  • Otsuka America Pharmaceutical, Inc.$678
  • Johnson & Johnson$673
  • Lundbeck LLC$639
  • plus $365 from 4 others

What the payments were for

  • Food & beverage$5,73594%
  • Education$3986%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,133 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate195$643,595
Abilify MaintenaAripiprazole70$208,358
Invega TrinzaPaliperidone Palmitate23$193,126
IngrezzaValbenazine Tosylate15$112,276
AristadaAripiprazole Lauroxil14$45,577
TrulicityDulaglutide13$12,397
Metformin Hcl32$8,036
Chlorpromazine Hcl36$4,970
Haloperidol Decanoate152$4,852
Divalproex Sodium ErDivalproex Sodium148$4,790
Quetiapine Fumarate227$2,060
Mirtazapine120$1,964
Trazodone Hcl145$1,877
Benztropine Mesylate162$1,848
Haloperidol71$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$673$836,721218 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$678$208,35870 claims
Neurocrine Biosciences, Inc.Ingrezza$1,688$112,27615 claims
Alkermes, Inc.Aristada$803$45,57714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →